Journal article
Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+Breast Cancer
Current oncology reports, Vol.24(12), pp.1779-1789
10/01/2022
DOI: 10.1007/s11912-022-01331-y
PMID: 36181611
Abstract
Purpose of Review Neoadjuvant, or pre-operative, therapy for the treatment of early-stage breast cancer has several potential benefits, especially for patients with triple-negative or HER2 + subtypes. This review provides an overview of optimal practices for utilizing neoadjuvant therapy, guidelines for decision-making, and ongoing clinical trials that are expected to help refine therapy choices. Recent Findings For triple-negative disease, the addition of the checkpoint inhibitor pembrolizumab to chemotherapy has shown remarkable efficacy, increasing response rates and survival. In the HER2 + setting, we are now able to safely avoid use of anthracyclines in most patients and refine adjuvant treatment choices based on response to neoadjuvant therapy. Results from recent clinical studies highlight advancements in systemic therapy and mark steps toward precision medicine, although reliable biomarkers of therapy response are still needed.
Details
- Title: Subtitle
- Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+Breast Cancer
- Creators
- Sneha Phadke - Roy J. and Lucille A. Carver College of Medicine
- Resource Type
- Journal article
- Publication Details
- Current oncology reports, Vol.24(12), pp.1779-1789
- Publisher
- Springer Nature
- DOI
- 10.1007/s11912-022-01331-y
- PMID
- 36181611
- ISSN
- 1523-3790
- eISSN
- 1534-6269
- Number of pages
- 11
- Language
- English
- Date published
- 10/01/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359760402771
Metrics
4 Record Views